Apnimed raised $192 million in a Nasdaq IPO and saw its shares surge on their first day, as investors backed a pill that could become the first oral drug for obstructive sleep apnea.

The company (ticker APMD) priced 12 million shares at $16 on August 2, and the stock closed at $25 — up 56%.

Lead drug oxnimbi (formerly AD109) is a once-nightly oral combination of atomoxetine, a generic ADHD medicine, and a novel compound called aroxybutynin. It was originally discovered at Brigham & Women’s Hospital.

What causes obstructive sleep apnea

The condition is a mechanical problem with a neurological cause. During sleep, muscle tone throughout the body decreases, including in the muscles holding the upper airway open.

In people with OSA, that relaxation lets the airway collapse. Breathing stops until falling oxygen and rising carbon dioxide trigger a brief arousal, muscle tone returns, the airway reopens, and the cycle repeats — sometimes hundreds of times a night.

The consequences follow from the fragmentation and the repeated oxygen dips: daytime sleepiness, and over years an increased risk of hypertension, cardiovascular disease and metabolic problems.

Why the drug combination makes sense

Both components act on the neural control of airway muscle tone, from different directions.

Atomoxetine increases norepinephrine signalling, which drives the nerves controlling the tongue and airway muscles — increasing tone during sleep, when it would otherwise fall.

The second component blocks muscarinic receptors, part of a pathway that suppresses airway muscle activity particularly during REM sleep, when apnea is often worst.

Neither alone had proved sufficient in earlier work. The combination addresses the excitatory and inhibitory sides of the same control system, which is the argument for pairing them rather than escalating a single agent.

Why an oral option would matter

Today, OSA is mainly managed with devices such as CPAP machines. Apnimed says oxnimbi could be “the first oral pill that treats an underlying cause of OSA,” distinct from Eli Lilly’s injectable Zepbound, approved for OSA in 2024 by driving weight loss.

CPAP is genuinely effective — it holds the airway open pneumatically and essentially eliminates apnea when used correctly. Its problem is adherence: a substantial proportion of patients cannot tolerate sleeping with a mask and pressurised air, and many abandon it within the first year.

The distinction from Zepbound is worth keeping clear. Weight loss reduces apnea in patients whose airway obstruction is driven by excess soft tissue, which is many but not all. A drug acting on muscle tone addresses the mechanism independently of weight.

The evidence

In two placebo-controlled Phase 3 trials across mild, moderate and severe OSA, the drug produced a statistically significant improvement in breathing-interruption measures and was well tolerated, with no serious drug-related severe adverse events.

The phrasing invites a specific question the summary does not answer: statistical significance establishes an effect exists, not its size. The standard measure counts breathing interruptions per hour, and what matters clinically is how far that falls and how many patients cross into a normal or mild range.

Against CPAP, which nearly eliminates events when worn, a partial reduction would be a meaningfully different product — potentially valuable for patients who will not use a device, without matching the device.

What is next

Apnimed submitted a New Drug Application in April 2026, with an FDA target decision date of February 28, 2027.

The company has raised roughly $389 million since 2017 plus $150 million in debt, and projects cash runway through mid-2028. Kevin Lind took over as CEO in June 2026.

How to read the first-day pop

Closing 56% above the offer price indicates demand substantially exceeding what the pricing anticipated.

How many people go undiagnosed

The commercial case for an oral OSA drug rests partly on a diagnosis gap that is unusually large even by the standards of chronic disease.

Population estimates put the number of adults with clinically significant obstructive sleep apnea far above the number diagnosed, with the majority never identified. The symptoms — snoring, daytime tiredness, poor concentration — are common, unglamorous and easily attributed to overwork or age.

Diagnosis has also historically required a sleep study, either an overnight stay in a laboratory or a home testing kit. Both are inconvenient enough to deter people whose complaint is that they feel tired, and referral pathways run through specialists in limited supply.

Home testing has improved access, and consumer wearables now flag possible apnea to people who had not considered it. What that produces is a growing population of newly identified patients, many with milder disease, for whom a nightly mask is a disproportionate response — which is precisely the group an oral option would serve, and part of why the market opportunity is larger than current CPAP prescribing suggests.

That is favourable for early investors and represents money the company did not raise — shares sold at $16 that the market valued at $25. For a company approaching a regulatory decision with a defined runway, the pricing gap is a real cost. Business news, not investment or medical advice.